Refine Search

Search Results -

Term	Documents
(19 NOT 20).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	63
(L19 NOT L20).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	63

Database:
- US Pre-Grant Publication Full-Text Database
- US Patents Full-Text Database
- US OCR Full-Text Database
- EPO Abstracts Database
- JPO Abstracts Database
- Derwent World Patents Index
- IBM Technical Disclosure Bulletins

Search: [ ] Refine Search

Recall Text | Clear | Interrupt

Search History

DATE: Tuesday, October 26, 2004 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=AND			
L21	L19 not L20	63	L21
L20	L19 and L17	8	L20
L19	L2 same (proliferation)	71	L19
L18	L17 not L11	265	L18
L17	L16 and L14	391	L17
L16	(inhibit or reduce) same (proliferation)	25725	L16
L15	L14 and L6	13	L15
L14	L13 and L3	555	L14
L13	L12 and L2	1348	L13
L12	(screening or testing or identifying) same (drug or inhibitor or agent)	109604	L12
L11	L10 and (induced adj proliferation)	127	L11

L10	L2 and (pravastatin or atorvastatin or simvastatin or lovstatin or pindolol or meththiotepin or metoprolol or paldolol)	344	L10
L9	L8 not L7	0	L9
L8	L6 and L2	15	L8
L7	L6 and L5	15	L7
L6	(inhibit or inhibitor or drug or agent) same (induced adj proliferation)	614	L6
L5	L4 and L2	2233	L5
L4	(heart adj valve) same (degeneration or thrombosis or calcification or disease)	2233	L4
L3	(heart adj valve) same (degeneration or throbosis or calcification or disease)	1972	L3
L2	(heart adj valve) or (valvular adj (tissue or endothelial))	8920	L2
L1	Rajamannan-Nalini-M$.in.	4	L1

END OF SEARCH HISTORY

PALM INTRANET

Day : Tuesday
Date: 10/26/2004
Time: 14:19:08

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name	First Name	
Rajamannan	Nalini	Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

```
                        Welcome to DialogClassic Web(tm)
 Dialog level 04.18.01D
Last logoff:  25oct04 09:12:20
Logon file001 26oct04 14:34:51
          *** ANNOUNCEMENT ***
                    ***
--Connect Time joins DialUnits as pricing options on Dialog.
See HELP CONNECT for information.
                    ***
--SourceOne patents are now delivered to your email inbox
as PDF replacing TIFF delivery. See HELP SOURCE1 for more
information.
                    ***
--Important Notice to Freelance Authors--
See HELP FREELANCE for more information
                    ***
NEW FILES RELEASED
***Beilstein Abstracts (File 393)
***Beilstein Facts (File 390)
***Beilstein Reactions (File 391)
***F-D-C Gold/Silver Sheet (File 184)
***BIOSIS Toxicology (File 157)
***IPA Toxicology (File 153)
                    ***
UPDATING RESUMED
                    *** RELOADED
***Toxfile (File 156)

REMOVED
***Textile Technology Digest (File 119)
                    ***

     >>> Enter BEGIN HOMEBASE for Dialog Announcements <<<
     >>>    of new databases, price changes, etc.      <<<
                    ****
KWIC is set to 50.
HILIGHT set on as ' '
 * * *

File   1:ERIC 1966-2004/Jul 21
       (c) format only 2004 The Dialog Corporation

      Set  Items  Description
      ---  -----  -----------
Cost is in DialUnits
?
B 155, 5, 73
       26oct04 14:35:04 User259876 Session D684.1
            $0.73    0.208 DialUnits File1
     $0.73  Estimated cost File1
     $0.05  INTERNET
     $0.78  Estimated cost this search
     $0.78  Estimated total session cost   0.208 DialUnits

SYSTEM:OS  - DIALOG OneSearch
  File 155:MEDLINE(R) 1951-2004/Oct W4
         (c) format only 2004 The Dialog Corp.
  File   5:Biosis Previews(R) 1969-2004/Oct W3
         (c) 2004 BIOSIS
  File  73:EMBASE 1974-2004/Oct W3
         (c) 2004 Elsevier Science B.V.

      Set  Items  Description
      ---  -----  -----------
?
```

```
S (HEART (W) VALVE) (W) (DEGENERATION OR THROMBOSIS OR CALCIFICATION)
          1845387  HEART
           204442  VALVE
           193224  DEGENERATION
           224910  THROMBOSIS
            63559  CALCIFICATION
      S1      269  (HEART (W) VALVE) (W) (DEGENERATION OR THROMBOSIS OR
                   CALCIFICATION)
?
S S1 (S) (INHIBITOR OR DRUG)
             269  S1
          964040  INHIBITOR
         8317261  DRUG
      S2      13  S1 (S) (INHIBITOR OR DRUG)
?
RD
...completed examining records
      S3       7  RD (unique items)
?
T S3/3,K/ALL
```

3/3,K/1 (Item 1 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

12819432 PMID: 7586894
Novel delivery of antiarrhythmic agents.
Labhasetwar V; Levy R J
University of Michigan Medical Center, Division of Pediatric Cardiology, Ann Arbor, USA.
Clinical pharmacokinetics (NEW ZEALAND) Jul 1995, 29 (1) p1-5, ISSN 0312-5963 Journal Code: 7606849
Contract/Grant No.: HL41663; HL; NHLBI
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... compounds, which are otherwise more potent and less toxic than available agents. The regional nature of the several cardiac diseases, such as ischaemia, restenosis or **heart valve calcification** , may require a high concentration of **drug** at the location of the disease, which by conventional routes may not be attainable due to systemic toxicity of the **drug** . Localised cardiac delivery of antiarrhythmic agents, based on **drug** -polymer implants, may have several advantages, including enhanced **drug** effects and reduced systemic **drug** toxicity. Computer-assisted automated feedback systems may further enhance the usefulness of this therapy in the clinical setting. Before clinical application of this method of **drug** delivery further study will be required, but it is hypothesised that pharmacokinetic variability for drugs delivered in this manner will be reduced and therefore efficacy...

3/3,K/2 (Item 2 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

07972580 PMID: 3144594
Controlled release of diphosphonates from synthetic polymers to inhibit calcification.
Golomb G
Department of Pharmacy, School of Pharmacy, Hebrew University of Jerusalem, Israel.
Journal of biomaterials applications (UNITED STATES) Oct 1987, 2 (2) p266-89, ISSN 0885-3282 Journal Code: 8813912

Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... bioprosthetic heart valves fabricated from glutaraldehyde pretreated porcine aortic valves or bovine pericardium. Formulation and evaluation of controlled-release drug delivery system to inhibit bioprosthetic **heart valve calcification** is reviewed.

3/3,K/3 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

07567869 PMID: 3116348
Prevention of leaflet calcification of bioprosthetic heart valves with diphosphonate injection therapy. Experimental studies of optimal dosages and therapeutic durations.
Levy R J; Schoen F J; Lund S A; Smith M S
Division of Pediatric Cardiology, C.S. Mott Children's Hospital, University of Michigan Medical Center, Ann Arbor 48109.
Journal of thoracic and cardiovascular surgery (UNITED STATES) Oct 1987, 94 (4) p551-7, ISSN 0022-5223 Journal Code: 0376343
Contract/Grant No.: HL32261; HL; NHLBI; HL32346; HL; NHLBI
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... received daily subcutaneous injections of the drug (1, 5, 10, 15, or 25 mg/kg/24 hr) for 21 days with maximal inhibition of bioprosthetic **heart valve calcification** at a dosage of 15 mg/kg/24 hr (calcium level of diphosphonate-treated bioprostheses 3.5 +/- 0.5 micrograms/ml; calcium level of control...
... mg), but with irreversibly diminished bone and somatic growth. A dosage optimum was observed at 10 mg/kg/24 hr with significant inhibition of bioprosthetic **heart valve calcification** (at 21 days, the calcium level was 16.4 +/- 3.6 micrograms/mg) and an absence of adverse effects on epiphyseal development and overall growth...

... more calcification after 21 days than did bioprostheses from animals treated for 2 or 3 weeks. Bioprostheses explanted after 110 days from animals receiving the **drug** (15 mg/kg/24 hr) for the first 3 weeks had calcification equivalent to that of untreated control rats. Diphosphonate (15 mg/kg/24 hr...

3/3,K/4 (Item 4 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

07483079 PMID: 3110404
Controlled-release drug delivery of diphosphonates to inhibit bioprosthetic heart valve calcification **: release rate modulation with silicone matrices via** drug **solubility and membrane coating.**
Golomb G; Dixon M; Smith M S; Schoen F J; Levy R J
Journal of pharmaceutical sciences (UNITED STATES) Apr 1987, 76 (4) p271-6, ISSN 0022-3549 Journal Code: 2985195R
Contract/Grant No.: HL32261; HL; NHLBI
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

Controlled-release drug delivery of diphosphonates to inhibit bioprosthetic heart valve calcification : **release rate modulation with silicone matrices via** drug **solubility and membrane coating.**

3/3,K/5 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0014260707 BIOSIS NO.: 200300219426
Mechanical prosthetic heart valve thrombosis: Fibrinolysis or surgery? A single center study about 253 patients.
AUTHOR: Roudaut R (Reprint); Lafitte S (Reprint); Roudaut M F (Reprint); Jais C (Reprint); Coste P (Reprint); Roques X (Reprint); Deville C (Reprint); Baudet E (Reprint)
AUTHOR ADDRESS: Hopital Cardiologique, Pessac, France**France
JOURNAL: European Heart Journal 23 (Abstract Supplement): p439 August-September 2002 2002
MEDIUM: print
CONFERENCE/MEETING: Congress of the European Society of Cardiology Berlin, Germany August 31-September 04, 2002; 20020831
SPONSOR: European Society of Cardiology
ISSN: 0195-668X _(ISSN print)
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Citation
LANGUAGE: English

DESCRIPTORS:
...DISEASES: heart disease, **drug** therapy, surgery

3/3,K/6 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0008253765 BIOSIS NO.: 199293096656
SCANNING ELECTRON MICROSCOPY STUDIES OF THE PREVENTION OF BIOPROSTHETIC HEART VALVE CALCIFICATION WITH CONTROLLED RELEASE POLYMERIC MATRICES
AUTHOR: PATHAK Y V (Reprint); BOYD J; JOHNSTON T P; LEVY J T; GOLOMB G; SCHOEN F J; LEVY R J
AUTHOR ADDRESS: R-5014 KRESGE II, UNIV MICH, ANN ARBOR, MICH 48109-0576, USA**USA
JOURNAL: Cells and Materials 1 (1): p65-72 1991
ISSN: 1051-6794
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

...ABSTRACT: consisting of either ethanehydroxydiphosphonate, FeCl3 or Al(NO3)3 coimplanted with bioprosthetic tissue prevent experimental bioprosthetic calcification. SEM has also been used to study the **drug** particle distribution in the controlled release matrices. Furthermore, matrix **drug** release in vitro and in vivo has also been characterized and quantified using SEM techniques.

3/3,K/7 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0006962522 BIOSIS NO.: 199039015911
CONTROLLED RELEASE IMPLANTS FOR CARDIOVASCULAR DISEASE
BOOK TITLE: ANDERSON, J. M., S. W. KIM AND K. KNUTSON (ED.). ADVANCES IN DRUG DELIVERY SYSTEMS, VOL. 4; INTERNATIONAL SYMPOSIUM ON RECENT ADVANCES IN DRUG DELIVERY SYSTEMS, SALT LAKE CITY, UTAH, USA, FEBRUARY 21-24,

1989. X+359P. ELSEVIER SCIENCE PUBLISHERS B.V.: AMSTERDAM, NETHERLANDS; NEW YORK, NEW YORK, USA. ILLUS
AUTHOR: LEVY R J (Reprint); JOHNSTON T P; SINTOV A; GOLOMB G
AUTHOR ADDRESS: DEP PEDIATR, UNIV MICH, R-5014 KRESGE II, 0576, ANN ARBOR, MICH 48109-0576, USA**USA
SERIES TITLE: Advances in Drug Delivery Systems p245-254 1990
ISBN: 0-444-88225-1
DOCUMENT TYPE: Book; Meeting
RECORD TYPE: Citation
LANGUAGE: ENGLISH

DESCRIPTORS: DOG RAT SHEEP VENTRICULAR TACHYCARDIA PROSTHETIC HEART VALVE CALCIFICATION ETHANEHYDROXYDIPHOSPHONATE CARDIOVASCULAR- **DRUG** LIDOCAINE HYDROCHLORIDE ANTIARRHYTHMIC- **DRUG**
?

```
Set      Items   Description
S1         269   (HEART (W) VALVE) (W) (DEGENERATION OR THROMBOSIS OR CALCI-
                 FICATION)
S2          13   S1 (S) (INHIBITOR OR DRUG)
S3           7   RD (unique items)
?
S S1 (S) (INDUCED W) PROLIFERATION)
>>>Unmatched parentheses
?
S S1 (S) (INDUCED (W) PROLIFERATION)
             269  S1
         3169280  INDUCED
          522377  PROLIFERATION
      S4       0  S1 (S) (INDUCED (W) PROLIFERATION)
?
S (INHIBITOR OR DRUG OR ANTAGONIST) (S) (PROLIFERATION AND (HEART (W) VALVE))
          964040  INHIBITOR
         8317261  DRUG
          436570  ANTAGONIST
          522377  PROLIFERATION
         1845387  HEART
          204442  VALVE
           50434  HEART(W)VALVE
      S5      12  (INHIBITOR OR DRUG OR ANTAGONIST) (S) (PROLIFERATION AND
                  (HEART (W) VALVE))
?
RD
...completed examining records
      S6       9  RD (unique items)
?
T S6/3,K/ALL
```

6/3,K/1 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

16932921 PMID: 15212624
Sarpogrelate: cardiovascular and renal clinical potential.
Doggrell Sheila A
Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand. s.doggrell@xtra.co.nz
Expert opinion on investigational drugs (England) Jul 2004, 13 (7) p865-74, ISSN 1744-7658 Journal Code: 9434197
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: In Process

Sarpogrelate is a selective 5-hydroxytryptamine receptor subtype 2A

(5-HT2A) **antagonist** . It is metabolised to racemic M-1 and both enantiomers of M-1 are also antagonists of 5-HT2A receptors. Sarpogrelate inhibits responses to 5-HT mediated by 5-HT2A receptors such as platelet aggregation, vasoconstriction and vascular smooth muscle **proliferation** . There is no information available on the pharmacokinetics of sarpogrelate. Sarpogrelate is efficacious in animal models of thrombosis, coronary artery spasm, atherosclerosis, restenosis, peripheral vascular...
... disease, myocardial infarction, diabetes and kidney disease. Small clinical trials indicate that sarpogrelate may be beneficial in the treatment of coronary artery disease, angina, restenosis, **heart valve** prostheses surgery, diabetes mellitus, Raynaud's phenomenon, systemic sclerosis and Buerger's disease. Larger, . randomised, double-blind, placebo-controlled clinical trials of sarpogrelate in intermittent...

6/3,K/2 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

14439580 PMID: 10433819
Diminished matrix metalloproteinase 2 (MMP-2) in ectomesenchyme-derived tissues of the Patch mutant mouse: regulation of MMP-2 by PDGF and effects on mesenchymal cell migration.
Robbins J R; McGuire P G; Wehrle-Haller B; Rogers S L
Department of Cell Biology and Physiology, University of New Mexico School of Medicine, 149 Basic Medical Sciences Building, Albuquerque, New Mexico, 87131, USA.
Developmental biology (UNITED STATES) Aug 15 1999, 212 (2) p255-63, ISSN 0012-1606 Journal Code: 0372762
Contract/Grant No.: T32HL07736; HL; NHLBI
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... significantly less. In addition, the migratory ability of branchial arch cells from normal explants could be reduced in a similar manner using a specific MMP **inhibitor** . Although it is still unclear whether the MMP-2 reduction is a direct result of the absence of response of Ph/Ph cells to PDGF...

6/3,K/3 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

11472750 PMID: 11581595
Operation for anorexigen-associated valvular heart disease.
Caccitolo J A; Connolly H M; Rubenson D S; Orszulak T A; Schaff H V
Division of Cardiovascular Surgery and Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA.
Journal of thoracic and cardiovascular surgery (United States) Oct 2001 , 122 (4) p656-64, ISSN 0022-5223 Journal Code: 0376343
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... valve replacement, 5 with concomitant aortic valve replacement. Excised valves demonstrated a glistening white appearance with plaque-like encasement of leaflets and chordae. Focal surface **proliferation** and fibrosis with a "stuck-on" appearance was consistently found. CONCLUSIONS: Anorexigen use may lead to severe multivalvular regurgitation with characteristic echocardiographic and pathologic findings. Recognition of **drug** -induced valvulopathy is important because of widespread use of these

medications and the uncertain natural history of the disease. Early surgical experience suggests that valve...

6/3,K/4 (Item 4 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

07035736 PMID: 4090558
[Rational hematologic diagnosis with reference to modern laboratory procedures]
Rationale hamatologische Diagnostik unter Berucksichtigung moderner Laboratoriumsverfahren.
Stobbe H
Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete (GERMANY, EAST) Nov 15 1985, 40 (22) p658-60, ISSN 0044-2542
Journal Code: 21730470R
Document type: Journal Article ; English Abstract
Languages: GERMAN
Main Citation Owner: NLM
Record type: Completed

The spectre of methods for the diagnostics and differentiation of haemolytic anaemias, particularly for the establishment of congenital, autoimmune haemolytic, **drug** -conditioned and other anaemias is treated. The clear delimitation of an iron deficiency from a disturbance of the iron distribution is advantageously to be achieved...

... haematopoietic stem cells are particularly evident in the aplastic syndrome of the bone marrow and further haematological diseases concerning the establishment of the intensiveness of **proliferation** . The classification of the acute leukemias demands conventional as well as cytochemical staining methods; recently, it is essentially improved using monoclonal antibodies. In leukemias cytogenetic...

6/3,K/5 (Item 5 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

06804443 PMID: 3922293
Influence of the developmental state of valvular lesions on the antimicrobial activity of cefotaxime in experimental enterococcal infections.
Sullam P M; Drake T A; Tauber M G; Hackbarth C J; Sande M A
Antimicrobial agents and chemotherapy (UNITED STATES) Mar 1985, 27 (3) p320-3, ISSN 0066-4804 Journal Code: 0315061
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

Descriptors: Cefotaxime--therapeutic use--TU; *Endocarditis, Bacterial --drug therapy--DT; *Heart Valve Diseases-- **drug** therapy--DT; *Streptococcal Infections--drug therapy--DT

6/3,K/6 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

12166070 EMBASE No: 2003270282
NFATc1 mediates vascular endothelial growth factor-induced proliferation of human pulmonary valve endothelial cells
Johnson E.N.; Lee Y.M.; Sander T.L.; Rabkin E.; Schoen F.J.; Kaushal S.;

Bischoff J.
J. Bischoff, Dept. of Surgery, Children's Hospital, 300 Longwood Ave., Boston, MA 02115 United States
AUTHOR EMAIL: joyce.bischoff@tch.harvard.edu
Journal of Biological Chemistry (J. BIOL. CHEM.) (United States) 17 JAN 2003, 278/3 (1686-1692)
CODEN: JBCHA ISSN: 0021-9258
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 36

...endothelial growth factor (VEGF) signaling through VEGF receptor 2. VEGF-induced NFATc1 nuclear translocation was inhibited by either cyclosporin A or a calcineurin-specific peptide **inhibitor** ; these findings suggest that VEGF stimulates NFATc1 nuclear import in human pulmonary valve endothelial cells by a calcineurin-dependent mechanism. Importantly, both cyclosporin A and the calcineurin-specific peptide **inhibitor** reduced VEGF-induced human pulmonary valve endothelial cell **proliferation** , indicating a functional role for NFATc1 in endothelial growth. In contrast, VEGF-induced **proliferation** of human dermal microvascular and human umbilical vein endothelial cells was not sensitive to cyclosporin A. Finally, NFATc1 was detected in the endothelium of human...

...valve leaflets by immunohistochemistry. These results suggest VEGF-induced NFATc1 activation may be an important mechanism in cardiac valve maintenance and function by enhancing endothelial **proliferation** .

6/3,K/7 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE

11742403 EMBASE No: 2002318036
Future potential indications for an oral thrombin inhibitor
ZUKUNFTIQES INDIKATIONSPOTENZIAL EINES ORALEN THROMBININHIBITORS
Haas S.
Dr. S. Haas, Inst. Exp. Onkol./Therapieforschung, Technische Universitat Munchen, Ismaninger Str. 22, 81675 Munchen Germany
AUTHOR EMAIL: sylvia.haas@lrz.tum.de
Hamostaseologie (HAMOSTASEOLOGIE) (Germany) 2002, 22/3 (118-125)
CODEN: HAEMD ISSN: 0720-9355
DOCUMENT TYPE: Journal ; Review
LANGUAGE: GERMAN SUMMARY LANGUAGE: ENGLISH; GERMAN
NUMBER OF REFERENCES: 35

...with food ingredients and drugs. The search for new antithrombotics with an improved safety/efficacy profile led to the development of the direct oral thrombin- **inhibitor** ximelagatran. It can be administered without routine monitoring of coagulation parameters and does not possess any of the previously mentioned limitations. The results from clinical...

...as an alternative anticoagulant in heparin induced thrombocytopenia and for prevention of thromboembolic complications in oncology. Because of the mitogenic effects of thrombin on the **proliferation** of tumour cells, additional experimental studies aiming at a potential inhibition of thrombin-triggered oncogenesis is of uttermost interest.

6/3,K/8 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE

11419458 EMBASE No: 2001432739
Cell proliferation in carcinoid valve disease: A mechanism for serotonin effects

Rajamannan N.M.; Caplice N.; Anthikad F.; Sebo T.J.; Orszulak T.A.; Edwards W.D.; Tajik J.; Schwartz R.S.
Dr. N.M. Rajamannan, Northwestern University Medical Sch., Division of Cardiology, 250 East Superior Street, Chicago, IL 60611 United States
Journal of Heart Valve Disease (J. HEART VALVE DIS.) (United Kingdom) 2001, 10/6 (827-831)
CODEN: JHVDE ISSN: 0966-8519
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 17

...proliferative effects of serotonin (10SUP-8to 10SUP-6M) on cultured porcine aortic valve cells via a [SUP3H]thymidine assay were determined in vitro. Serotonin receptor **antagonist** studies in culture were also performed using methiotepin, a 5HTSUB1b **antagonist** , and ketanserin, a 5HTSUB2 receptor **antagonist** , to determine the mechanism of serotonin action. The ex-vivo **proliferation** level in human carcinoid (n = 26) and normal valves (n = 10) was compared using proliferating cell nuclear antigen (PCNA) staining, a marker for **proliferation** . Identification and localization of specific 5HT receptor was assessed by immunostaining for serotonin receptors in the valves. Results: Serotonin increased valvular **proliferation** in vitro in a dose-dependent manner (10-fold increase) (p <0.001), and this mitogenic effect was inhibited by methiotepin but not ketanserin. In human carcinoid heart valves the level of **proliferation** was 35-fold higher than in normal human valves (p <0.001). 5HTSUB1b receptors were found only in the carcinoid valves, and not in the normal valves. Conclusion: Serotonin is a powerful mitogen for valvular subendocardial cells. The mitogenic effect is at least partly mediated via 5HTSUB1b receptors. Subendothelial cell **proliferation** is significantly elevated in human carcinoid valves in vivo. The data suggest a mechanism whereby serotonin may contribute to valvular **proliferation** in carcinoid heart disease.

6/3,K/9 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE

01495127 EMBASE No: 1979216176
Some recent advances in cardiac pathology
Billingham M.E.
Dept. Pathol., Stanford Univ. Sch. Med., Stanford, Calif. United States
Human Pathology (HUM. PATHOL.) (United States) 1979, 10/4 (367-386)
CODEN: HPCQA
DOCUMENT TYPE: Journal
LANGUAGE: ENGLISH

This article has reviewed some recent advances in human cardiac pathology. The areas selected were cardiac transplant pathology, the lesions of **drug** cardiotoxicity, and the morphology of tissue **heart valve** replacements. The **proliferation** of work in the first two areas is largely the result of the successful introduction of a new procedure, endomyocardial biopsy, which has made it...
?

Set	Items	Description
S1	269	(HEART (W) VALVE) (W) (DEGENERATION OR THROMBOSIS OR CALCIFICATION)
S2	13	S1 (S) (INHIBITOR OR DRUG)
S3	7	RD (unique items)
S4	0	S1 (S) (INDUCED (W) PROLIFERATION)
S5	12	(INHIBITOR OR DRUG OR ANTAGONIST) (S) (PROLIFERATION AND (-HEART (W) VALVE))
S6	9	RD (unique items)

?

```
S (SCREENING OR IDENTIFYING) (S) (INHIBITORS OR DRUGS OR ANTAGONISTS)
          546440  SCREENING
          139087  IDENTIFYING
          834708  INHIBITORS
          954099  DRUGS
          563388  ANTAGONISTS
      S7   28060  (SCREENING OR IDENTIFYING) (S) (INHIBITORS OR DRUGS OR
                  ANTAGONISTS)
?
S S1 AND S7
             269  S1
           28060  S7
      S8       1  S1 AND S7
?
T S8/3,K/ALL

  8/3,K/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2004 BIOSIS. All rts. reserv.

0014679298   BIOSIS NO.: 200400060055
 Bioprosthetic heart valves
AUTHOR: Rajamannan Nalini M (Reprint)
AUTHOR ADDRESS: Rochester, MN, USA**USA
JOURNAL: Official Gazette of the United States Patent and Trademark Office
Patents  1277 (2): Dec. 9, 2003 2003
MEDIUM: e-file
PATENT NUMBER: US 6660260  PATENT DATE GRANTED: December 09, 2003 20031209
PATENT CLASSIFICATION: 424-9321  PATENT ASSIGNEE: Mayo Foundation for
Medical Education and Research  PATENT COUNTRY: USA
ISSN: 0098-1133 _(ISSN print)
DOCUMENT TYPE: Patent
RECORD TYPE: Abstract
LANGUAGE: English

...ABSTRACT: heart valve cells and heart valve cusps as well as methods for
  making heart valves. The invention also provides methods and materials
  for (1) slowing heart  valve  degeneration , thrombosis, and
  calcification, (2) treating carcinoid heart disease, (3) identifying
 inhibitors of heart  valve  degeneration , thrombosis, and
  calcification, and (4) determining the safety of drugs .
DESCRIPTORS:
  ...DISEASES: heart  valve  degeneration --
?

Set     Items   Description
S1        269   (HEART (W) VALVE) (W) (DEGENERATION OR THROMBOSIS OR CALCI-
                FICATION)
S2         13   S1 (S) (INHIBITOR OR DRUG)
S3          7   RD (unique items)
S4          0   S1 (S) (INDUCED (W) PROLIFERATION)
S5         12   (INHIBITOR OR DRUG OR ANTAGONIST) (S) (PROLIFERATION AND (-
                HEART (W) VALVE))
S6          9   RD (unique items)
S7      28060   (SCREENING OR IDENTIFYING) (S) (INHIBITORS OR DRUGS OR ANT-
                AGONISTS)
S8          1   S1 AND S7
?
S (HEART (W) VALVE) (S) (PROLIFERATION)
         1845387  HEART
          204442  VALVE
          522377  PROLIFERATION
      S9      56  (HEART (W) VALVE) (S) (PROLIFERATION)
?
S S7 AND S9
```

```
            28060  S7
               56  S9
     S10        0  S7 AND S9
?
S S9 AND (INHIBITOR? OR ANTAGONIST? OR DRUG?)
Processing
               56  S9
          1935976  INHIBITOR?
           897063  ANTAGONIST?
          8640436  DRUG?
     S11       14  S9 AND (INHIBITOR? OR ANTAGONIST? OR DRUG?)
?
RD
...completed examining records
     S12        8  RD (unique items)
?
T S12/3,K/ALL
```

12/3,K/1 (Item 1 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

16932921 PMID: 15212624

Sarpogrelate: cardiovascular and renal clinical potential.

Doggrell Sheila A
Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand. s.doggrell@xtra.co.nz

Expert opinion on investigational drugs (England) Jul 2004, 13 (7) p865-74, ISSN 1744-7658 Journal Code: 9434197
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: In Process

Sarpogrelate is a selective 5-hydroxytryptamine receptor subtype 2A (5-HT2A) **antagonist** . It is metabolised to racemic M-1 and both enantiomers of M-1 are also **antagonists** of 5-HT2A receptors. Sarpogrelate inhibits responses to 5-HT mediated by 5-HT2A receptors such as platelet aggregation, vasoconstriction and vascular smooth muscle proliferation...

... disease, myocardial infarction, diabetes and kidney disease. Small clinical trials indicate that sarpogrelate may be beneficial in the treatment of coronary artery disease, angina, restenosis, **heart valve** prostheses surgery, diabetes mellitus, Raynaud's phenomenon, systemic sclerosis and Buerger's disease. Larger, randomised, double-blind, placebo-controlled clinical trials of sarpogrelate in intermittent...

12/3,K/2 (Item 2 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

14439580 PMID: 10433819

Diminished matrix metalloproteinase 2 (MMP-2) in ectomesenchyme-derived tissues of the Patch mutant mouse: regulation of MMP-2 by PDGF and effects on mesenchymal cell migration.

Robbins J R; McGuire P G; Wehrle-Haller B; Rogers S L
Department of Cell Biology and Physiology, University of New Mexico School of Medicine, 149 Basic Medical Sciences Building, Albuquerque, New Mexico, 87131, USA.

Developmental biology (UNITED STATES) Aug 15 1999, 212 (2) p255-63, ISSN 0012-1606 Journal Code: 0372762
Contract/Grant No.: T32HL07736; HL; NHLBI
Document type: Journal Article
Languages: ENGLISH

Main Citation Owner: NLM
Record type: Completed

... receptor. Homozygous (Ph/Ph) embryos exhibit multiple connective tissue defects including cleft face (involving the first branchial arch and frontonasal processes), incomplete heart septation, and **heart valve** abnormalities before they die in utero. Analyses of the cell biology underlying the defects in Ph/Ph embryos have revealed a deficit in a matrix ...

...significantly less. In addition, the migratory ability of branchial arch cells from normal explants could be reduced in a similar manner using a specific MMP **inhibitor** . Although it is still unclear whether the MMP-2 reduction is a direct result of the absence of response of Ph/Ph cells to PDGF...
; Animals; Branchial Region--cytology--CY; Branchial Region--embryology --EM; Branchial Region--enzymology--EN; Face--embryology--EM; Gelatinase A ; Gelatinases-- **antagonists** and **inhibitors** --AI; Heart--embryology--EM; Mesoderm--enzymology--EN; Metalloendopeptidases-- **antagonists** and **inhibitors** --AI; Mice; Mice, Mutant Strains; Morphogenesis; Myocardium --enzymology--EN; Skull--embryology--EM; Tissue Culture

12/3,K/3 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

13118099 PMID: 8784007
Impact of glutaraldehyde on calcification of pericardial bioprosthetic heart valve material.
Grabenwoger M; Sider J; Fitzal F; Zelenka C; Windberger U; Grimm M; Moritz A; Bock P; Wolner E
Department of Cardio-Thoracic Surgery, University of Vienna, Austria.
Annals of thoracic surgery (UNITED STATES) Sep 1996, 62 (3) p772-7, ISSN 0003-4975 Journal Code: 15030100R
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... by dye-mediated photooxidation showed no calcification after 63 days of subcutaneous implantation (1.0 +/- 0.4 mg Ca2+/g dry weight). Regular endothelial cell **proliferation** was observed on photooxidized and L-glutamic acid-treated tissue, whereas conventionally treated tissue caused endothelial cell death. CONCLUSIONS: This study underlines the detrimental role of glutaraldehyde in the calcification process of bioprosthetic **heart valve** materials and emphasizes alternative preservation methods that reduce or avoid the use of glutaraldehyde.
Descriptors: Bioprosthesis; *Calcinosis--pathology--PA; *Glutaral --pharmacology--PD; *Heart Valve Prosthesis; *Pericardium-- **drug** effects --DE

12/3,K/4 (Item 4 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

11208023 PMID: 11245774
The genetics and physiology of polycystic kidney disease.
Calvet J P; Grantham J J
Department of Biochemistry, Kidney Institute, University of Kansas Medical Center, Kansas City, KS, USA. jcalvet@kumc.edu
Seminars in nephrology (United States) Mar 2001, 21 (2) p107-23, ISSN 0270-9295 Journal Code: 8110298
Document type: Journal Article; Review; Review Literature

Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... 1 transcription factor. In addition, polycystin-2 may function in mediating calcium flux. The pathogenesis of cyst formation is currently thought to involve increased cell **proliferation** , fluid accumulation, and basement membrane remodeling. It now appears that cyclic adenosine monophosphate (cAMP) metabolism is a central component of cyst formation, stimulating apical chloride...

... cyst fluid. Recent evidence has shown that ADPKD cells also have an altered responsiveness to cyclic AMP. In contrast to normal kidney cells whose cell **proliferation** is inhibited by cyclic AMP, ADPKD cells are stimulated to proliferate. Thus, it is likely that an alteration in polycystin function transforms the normal cellular phenotype to one that responds to elevated cyclic AMP by an increased rate of cell **proliferation** and that the enlarging cyst expands by an increased rate of cyclic AMP-driven fluid secretion. Cyclic AMP and growth factors, including epidermal growth factor...

... effects to accelerate the enlargement of ADPKD cysts, and thereby to contribute to the progression of the disease. This knowledge should facilitate the discovery of **inhibitors** of signal transduction cascades that can be used in the treatment of ADPKD. Copyright 2001 by W.B. Saunders Company

12/3,K/5 (Item 5 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.

09132515 PMID: 1728078
Glutaraldehyde affects biocompatibility of bioprosthetic heart valves.
Grimm M; Eybl E; Grabenwoger M; Spreitzer H; Jager W; Grimm G; Bock P; Muller M M; Wolner E
Second Department of Surgery, University of Vienna, Austria.
Surgery (UNITED STATES) Jan 1992, 111 (1) p74-8, ISSN 0039-6060 Journal Code: 0417347
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... washing solutions was found by high performance liquid chromatography (up to 1.8 ppm of glutaraldehyde per gram of dry tissue). In vitro endothelial cell **proliferation** rate was impaired dose-dependently in the presence of increasing glutaraldehyde concentrations of the cultivation medium (r = 0.9; p less than 0.05). Cultivation...
; Animals; Cattle; Cell Division-- **drug** effects--DE; Cells, Cultured; Endothelium, Vascular--cytology--CY; Glutaral--analysis--AN; Materials Testing

12/3,K/6 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2004 Elsevier Science B.V. All rts. reserv.

12788379 EMBASE No: 2004382559
Heart valve development: Endothelial cell signaling and differentiation
Armstrong E.J.; Bischoff J.
Dr. J. Bischoff, Vascular Biology Program, Children's Hospital Boston, 300 Longwood Ave, Boston, MA 02115 United States
AUTHOR EMAIL: joyce.bischoff@childrens.harvard.edu
Circulation Research (CIRC. RES.) (United States) 03 SEP 2004, 95/5

(459-470)
CODEN: CIRUA ISSN: 0009-7330
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 99

...beta-catenin, BMP/TGF-beta, ErbB, and NF1/Ras. Based on the interactions among and relative timing of these pathways, a signaling network model for **heart valve** development is proposed.
DRUG DESCRIPTORS:
...epidermal growth factor receptor 2--endogenous compound--ec; epidermal growth factor receptor 3--endogenous compound--ec; epidermal growth factor receptor 4--endogenous compound--ec; unclassified **drug**

12/3,K/7 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE

05146863 EMBASE No: 1992287096
Endothelial cell lining of bioprosthetic heart valve materials
Eybl E.; Grimm M.; Grabenwoger M.; Bock P.; Muller M.M.; Wolner E.
Second Department of Surgery, Zentrallabor B 800, University of Vienna, Spitalgasse 23,A-1090 Vienna Austria
Journal of Thoracic and Cardiovascular Surgery (J. THORAC. CARDIOVASC. SURG.) (United States) 1992, 104/3 (763-769)
CODEN: JTCSA ISSN: 0022-5223
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

...of antithrombogenic potency of the seeded cells on L-glutamic acid-treated valve material was proved by regular release of prostacyclin. We conclude that bioprosthetic **heart valve** materials can be lined with endothelial cells if toxic glutaraldehyde released from the bioprostheses is eliminated.
DRUG DESCRIPTORS:
collagen; fibronectin; glutamic acid; glutaraldehyde-- **drug** toxicity--to; prostacyclin--endogenous compound--ec

12/3,K/8 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE

01495127 EMBASE No: 1979216176
Some recent advances in cardiac pathology
Billingham M.E.
Dept. Pathol., Stanford Univ. Sch. Med., Stanford, Calif. United States
Human Pathology (HUM. PATHOL.) (United States) 1979, 10/4 (367-386)
CODEN: HPCQA
DOCUMENT TYPE: Journal
LANGUAGE: ENGLISH

This article has reviewed some recent advances in human cardiac pathology. The areas selected were cardiac transplant pathology, the lesions of **drug** cardiotoxicity, and the morphology of tissue **heart valve** replacements. The **proliferation** of work in the first two areas is largely the result of the successful introduction of a new procedure, endomyocardial biopsy, which has made it...
DRUG DESCRIPTORS:
* **drug**
MEDICAL DESCRIPTORS:
electron microscopy; histology; immunology; heart; adverse **drug** reaction; review
?

```
Set     Items   Description
S1        269   (HEART (W) VALVE) (W) (DEGENERATION OR THROMBOSIS OR CALCI-
                FICATION)
S2         13   S1 (S) (INHIBITOR OR DRUG)
S3          7   RD (unique items)
S4          0   S1 (S) (INDUCED (W) PROLIFERATION)
S5         12   (INHIBITOR OR DRUG OR ANTAGONIST) (S) (PROLIFERATION AND (-
                HEART (W) VALVE))
S6          9   RD (unique items)
S7      28060   (SCREENING OR IDENTIFYING) (S) (INHIBITORS OR DRUGS OR ANT-
                AGONISTS)
S8          1   S1 AND S7
S9         56   (HEART (W) VALVE) (S) (PROLIFERATION)
S10         0   S7 AND S9
S11        14   S9 AND (INHIBITOR? OR ANTAGONIST? OR DRUG?)
S12         8   RD (unique items)
?
S S7 AND (PRAVASTATIN OR ATORVASTATIN OR SIMVASTATIN OR LOVSTATIN OR PINDOLOL OR MET
           28060  S7
           10542  PRAVASTATIN
            6824  ATORVASTATIN
           13403  SIMVASTATIN
               7  LOVSTATIN
           16525  PINDOLOL
               0  METHTHIOTEPIN
           25629  METOPROLOL
               0  PALDOLOL
     S13     277  S7 AND (PRAVASTATIN OR ATORVASTATIN OR SIMVASTATIN OR
                  LOVSTATIN OR PINDOLOL OR METHTHIOTEPIN OR METOPROLOL OR
                  PALDOLOL)
?
S S1 AND S13
             269  S1
             277  S13
     S14       0  S1 AND S13
?
S S13 AND (HEART (W) VALVE)
             277  S13
         1845387  HEART
          204442  VALVE
           50434  HEART(W)VALVE
     S15       0  S13 AND (HEART (W) VALVE)
?
S (INHIBITED OR REDUCED) (S) (PROLIFERATION AND (HEART (W) VALVES))
          912838  INHIBITED
         1711980  REDUCED
          522377  PROLIFERATION
         1845387  HEART
           41098  VALVES
            9808  HEART(W)VALVES
     S16      18  (INHIBITED OR REDUCED) (S) (PROLIFERATION AND (HEART (W)
                  VALVES))
?
S S13 AND S16
             277  S13
              18  S16
     S17       0  S13 AND S16
?
RD S18
>>>Set 18 has not yet been created.
?
RD S16
...completed examining records
     S18       8  RD S16 (unique items)
```

?
T S18/3,K/ALL

18/3,K/1 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

14290451 PMID: 10194805
Bisdiamine inhibits extracellular matrix formation and cell proliferation of atrioventricular mesenchyme from developing chick heart valves.
Choy M; Oltjen S L; Moon A J; Armstrong M T; Armstrong P B
Division of Pediatric Cardiology, University of California Davis Medical Center, Sacramento 95817, USA. mchoy@ucdavis.edu
Teratology (UNITED STATES) Mar 1999, 59 (3) p148-55, ISSN 0040-3709 Journal Code: 0153257
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... on mesenchymal cells grown in aggregate culture isolated from the developing atrioventricular valves of the stage-36 chick embryo. Fibronectin extracellular matrix formation and cell **proliferation** in the aggregates were assessed in various media. Chick serum stimulated the cells to produce an extracellular matrix and to divide, and the inclusion of bisdiamine **inhibited** both responses. If we isolated an extracellular matrix from a monolayer of mesenchymal cells and added the sonicated matrix to the medium containing serum and...
... attach to an intact extracellular matrix to begin cell division. Thus, we suggest that bisdiamine inhibits the normal formation of the extracellular matrix, leading to **reduced** cell **proliferation** , but it does not affect matrix-cell interaction. The lack of cushion growth in situ may be the cause of AVSD or TA.

18/3,K/2 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

14210123 PMID: 9930452
Effect of antibiotic pretreatment on immunogenicity of human heart valves and component cells.
Johnson D L; Sloan C; O'Halloran A; Yacoub M H
Department of Cardiothoracic Surgery, National Heart and Lung Institute, Imperial College at Harefield Hospital, Heart Science Centre, Middlesex, United Kingdom.
Annals of thoracic surgery (UNITED STATES) Dec 1998, 66 (6 Suppl) pS221-4, ISSN 0003-4975 Journal Code: 15030100R
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... low-dose antibiotics, peripheral blood mononuclear cells and human allogenic T cells were cocultured with antibiotic-treated valve discs, cultured valve endothelial cells, and fibroblasts. **Proliferation** was measured by uptake of thymidine labeled with hydrogen 3. RESULTS: Untreated tissue pieces stimulate peripheral blood mononuclear cells (4,080+/-980 cpm) at day...
... study shows that valve tissue is immunogenic and this immunogenicity is mediated mainly by endothelial cells. However, the immunostimulatory potential of the valve can be **reduced** by incubating the solution in an antibiotic cocktail.

18/3,K/3 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

13165284 PMID: 8834727
In vitro endothelialization of bioprosthetic heart valves.
Fischlein T; Fasol R
Department of Cardiac Surgery Grosshadern Medical Center, University of Munich, Germany.
Journal of heart valve disease (ENGLAND) Jan 1996, 5 (1) p58-65, ISSN 0966-8519 Journal Code: 9312096
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... to conventional bioprosthetic heart valves, glutaraldehyde preserved porcine aortic valve leaflets were precoated with fibronectin-heparin and acidic fibroblast growth factor (aFGF) to enhance cell **proliferation** . Furthermore, different methods of storage and preservation (1.0% benzoic acid, 1.0% sorbic acid, 0.05% and 0.5% dialdehyde starch) were compared to ...

...aFGF protein and endothelial cells improved in vitro and in vivo results significantly. CONCLUSIONS: Our study shows that endothelial cell growth as well as significantly **reduced** in vivo degeneration and mineralization of valve leaflets may be feasible if bioprosthetic **heart valves** are processed according to alternative, non-toxic conservation procedures and are precoated with angiogenic growth factor protein.

18/3,K/4 (Item 4 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

13103742 PMID: 8725286
Fibroblast growth factor-2 stimulates embryonic cardiac mesenchymal cell proliferation.
Choy M; Oltjen S L; Otani Y S; Armstrong M T; Armstrong P B
Division of Pediatric Cardiology, University of California Davis Medical Center, Sacramento 95817, USA.
Developmental dynamics - an official publication of the American Association of Anatomists (UNITED STATES) Jun 1996, 206 (2) p193-200, ISSN 1058-8388 Journal Code: 9201927
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

The **proliferation** response of stage 36 chick atrioventricular valve mesenchymal cells to fibroblast growth factor-2 (FGF-2) was studied in the tissue-like environment of three...

... inclusion of Arg-Gly-Asp-containing peptides, which compete with fibronectin for binding to the cell surface alpha 5 beta 1 integrin receptors, abolished the **proliferation** effects of FGF-2. Inhibition of sulfation of cell surface glycosaminoglycans by treatment with sodium chlorate significantly **reduced** both the formation of the fibronectin matrix and cell **proliferation** in response to FGF-2, suggesting an involvement of the low-affinity sulfated glycosaminoglycan FGF receptor system. Thus, the FGF-stimulated growth of embryonic atrioventricular...

18/3,K/5 (Item 5 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

12387819 PMID: 12773386
Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling.
Jackson Leslie F; Qiu Ting Hu; Sunnarborg Susan W; Chang Aileen; Zhang Chunlian; Patterson Cam; Lee David C
Department of Biochemistry & Biophysics, UNC Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.
EMBO journal (England) Jun 2 2003, 22 (11) p2704-16, ISSN 0261-4189 Journal Code: 8208664
Contract/Grant No.: AG021096; AG; NIA; CA43793; CA; NCI; CA61896; CA; NCI ; CA85410; CA; NCI; HL65619; HL; NHLBI
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... double null HB-EGF(-/-)/BTC(-/-) mice was further reduced, apparently due to accelerated heart failure. HB-EGF(-/-) newborns had enlarged and malformed semilunar and atrioventricular **heart valves** , and hypoplastic, poorly differentiated lungs. Defective cardiac valvulogenesis was the result of abnormal mesenchymal cell **proliferation** during remodeling, and was associated with dramatic increases in activated Smad1/5/8. Consistent with the phenotype, HB-EGF transcripts were localized to endocardial cells ...

18/3,K/6 (Item 6 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

11585869 PMID: 11767194
Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects.
Rajamannan N M; Caplice N; Anthikad F; Sebo T J; Orszulak T A; Edwards W D; Tajik J; Schwartz R S
Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA.
Journal of heart valve disease (England) Nov 2001, 10 (6) p827-31, ISSN 0966-8519 Journal Code: 9312096
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

...culture were also performed using methiotepin, a 5HT1b antagonist, and ketanserin, a 5HT2 receptor antagonist, to determine the mechanism of serotonin action. The ex-vivo **proliferation** level in human carcinoid (n = 26) and normal valves (n = 10) was compared using proliferating cell nuclear antigen (PCNA) staining, a marker for **proliferation** . Identification and localization of specific 5HT receptor was assessed by immunostaining for serotonin receptors in the valves. RESULTS: Serotonin increased valvular **proliferation** in vitro in a dose-dependent manner (10-fold increase) (p <0.001), and this mitogenic effect was **inhibited** by methiotepin but not ketanserin. In human carcinoid **heart valves** the level of **proliferation** was 35-fold higher than in normal human valves (p <0.001). 5HT1b receptors were found only in the carcinoid valves, and not in the normal valves. CONCLUSION: Serotonin is a powerful mitogen for valvular subendocardial cells. The mitogenic effect is at least partly mediated via 5HT1b receptors. Subendothelial cell **proliferation** is significantly elevated in human carcinoid valves in vivo. The data suggest a mechanism whereby serotonin may contribute to valvular **proliferation** in carcinoid heart disease.

18/3,K/7 (Item 7 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

10289041 PMID: 7986560
Integrity and viability of homograft valves.
Fischlein T; Schutz A; Uhlig A; Frey R; Krupa W; Babic R; Thiery J; Reichart B
Department of Cardiac Surgery, University of Munich, Germany.
European journal of cardio-thoracic surgery - official journal of the European Association for Cardio-thoracic Surgery (GERMANY) 1994, 8 (8) p425-30, ISSN 1010-7940 Journal Code: 8804069
Comment in Eur J Cardiothorac Surg. 1995;9(2) 113; Comment in PMID 7748572
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

... 3 days beforehand. Morphological observations were made using light and electron microscopy and, in order to characterize the endothelial cell viability, a non-radioactive cell **proliferation** assay was used. The PGI2 secretion of the remaining endothelium was defined as the 6-keto-prostaglandin F1 alpha metabolite by an enzyme immunoassay. Observations...
... of HBD homografts was maintained was confirmed by proven PGI2 secretion (6150 +/- 1200 pg/3 ml M199 after cryopreservation), whereas specimens from NHBD showed a **reduced** (1950 +/- 730 pg/3 ml M199) and, after cryopreservation, almost no release (P < 0.0001).(ABSTRACT TRUNCATED AT 250 WORDS)

18/3,K/8 (Item 8 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

07260406 PMID: 3490326
Porcine heart valves produce a protein that induces cell-mediated connective tissue degradation: II. Biochemical properties of the partially purified protein.
Decker R S; Henney A M; Dingle J T
Circulation research (UNITED STATES) Sep 1986, 59 (3) p329-41, ISSN 0009-7330 Journal Code: 0047103
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

...release of glycosaminoglycans from cultured cartilage and mitral valve and provoked porcine valves to degrade their own collagen extracellular matrix. The release of hydroxyproline was **inhibited** by corticosteroids, whereas proteoglycan breakdown was not. Partially pure preparations of CCF and synovial catabolin stimulated murine thymocyte **proliferation** ; moreover, that activity was almost totally abolished by an antibody raised against pure porcine interleukin-1. These observations suggest that CCF may represent a catabolic...
?

Set	Items	Description
S1	269	(HEART (W) VALVE) (W) (DEGENERATION OR THROMBOSIS OR CALCI-FICATION)
S2	13	S1 (S) (INHIBITOR OR DRUG)
S3	7	RD (unique items)

```
S4            0   S1 (S) (INDUCED (W) PROLIFERATION)
S5           12   (INHIBITOR OR DRUG OR ANTAGONIST) (S) (PROLIFERATION AND (-
               HEART (W) VALVE))
S6            9   RD (unique items)
S7        28060   (SCREENING OR IDENTIFYING) (S) (INHIBITORS OR DRUGS OR ANT-
               AGONISTS)
S8            1   S1 AND S7
S9           56   (HEART (W) VALVE) (S) (PROLIFERATION)
S10           0   S7 AND S9
S11          14   S9 AND (INHIBITOR? OR ANTAGONIST? OR DRUG?)
S12           8   RD (unique items)
S13         277   S7 AND (PRAVASTATIN OR ATORVASTATIN OR SIMVASTATIN OR LOVS-
               TATIN OR PINDOLOL OR METHTHIOTEPIN OR METOPROLOL OR PALDOLOL)
S14           0   S1 AND S13
S15           0   S13 AND (HEART (W) VALVE)
S16          18   (INHIBITED OR REDUCED) (S) (PROLIFERATION AND (HEART (W) V-
               ALVES))
S17           0   S13 AND S16
S18           8   RD S16 (unique items)
?
COST
        26oct04 15:06:34 User259876 Session D684.2
             $6.31    1.971 DialUnits File155
                $4.62  22 Type(s) in Format  3
             $4.62  22 Types
     $10.93  Estimated cost File155
             $7.54    1.347 DialUnits File5
                $7.00  4 Type(s) in Format  3
             $7.00  4 Types
     $14.54  Estimated cost File5
            $27.62    2.819 DialUnits File73
               $18.90  7 Type(s) in Format  3
            $18.90  7 Types
     $46.52  Estimated cost File73
             OneSearch, 3 files,  6.137 DialUnits FileOS
      $8.00  INTERNET
     $79.99  Estimated cost this search
     $80.77  Estimated total session cost   6.345 DialUnits
?
```

Return to logon page!